I'll verify who "Peter" is in this Supreme Court case caption before writing.
Confirmed the key fact. Let me verify a few details.
Entity note: "Peter" is not a company
The entry "Peter" in our database does not correspond to an operating company or a patent-assertion entity. It is Laura A. Peter, then Deputy Under Secretary of Commerce for Intellectual Property and Deputy Director of the U.S. Patent and Trademark Office (USPTO), named as respondent/intervenor in the Supreme Court caption. She was appointed effective November 13, 2018 and served through the first Trump administration; her prior roles include Deputy General Counsel of A10 Networks, VP and General Counsel of Immersion Corporation, and Assistant General Counsel/Director of IP at Foundry Networks (IPWatchdog; USPTO/Commerce Department releases; ChIPs bio). There is no private company profile, revenue, headcount, or product line to report for her.
Overview / operations. As a federal official, "Peter" has no products or services. The office she held sits within the USPTO, a federal agency that her official bio describes as managing roughly 13,000 employees and a ~$3.5 billion annual budget — figures attributable to the agency, not to an individual enterprise. Ownership status, ticker, and founding year are not applicable.
Litigation posture. The case data shows 0 plaintiff appearances and 1 defendant appearance, all at the Supreme Court. That pattern reflects nominal-party status rather than commercial litigation activity: the USPTO Deputy Director is sued in an official capacity when the government intervenes to defend the constitutionality of America Invents Act post-grant proceedings.
Notable case. Celgene Corp. v. Peter, No. 19-1074 (U.S. 2019 Term). Celgene petitioned for certiorari on February 26, 2020, asking whether retroactive application of inter partes review to pre-AIA patents violates the Fifth Amendment Takings Clause — a question expressly left open in Oil States (2018). The government, represented through Deputy Director Peter, opposed. The petition followed Celgene Corp. v. Peter, 931 F.3d 1342 (Fed. Cir. July 30, 2019), which affirmed PTAB obviousness findings and rejected the takings challenge; en banc rehearing was denied December 9, 2019. The Supreme Court denied certiorari on June 22, 2020. Underlying IPRs (IPR2015-01092/-01096/-01102/-01103) were brought by the Coalition for Affordable Drugs VI, LLC against Celgene patents on methods of safely administering teratogenic agents such as thalidomide. No Eastern District of Texas venue appears here.